Advertisement

Volume 129, Issue 24

Cover Figure:  Myeloid p53 promotes thrombus resolution. See the article by
Mukhopadhyay et al.

WASHINGTON, June 15, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
and
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma
Two papers in this week’s issue report phase 1 clinical trial results of the XPO1 inhibitor selinexor in relapsed or refractory acute myeloid leukemia (AML) and non–Hodgkin lymphoma (NHL). Garzon et al and Kuruvilla et al demonstrate acceptable toxicity and a modest response rate in AML and NHL, respectively.

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity
The most-feared complication of factor VIII replacement in hemophilia is the development of neutralizing antibodies. In a Perspectives article, Lai et al present a lucid analysis of the potential mechanisms governing relative immunogenicity and risk of inhibitor development among plasma-derived and recombinant factor VIII products.

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia
and
Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations
Rahman et al and Hu et al demonstrate that somatic mutations in noncoding sequences alter transcription factor binding sites and increase expression of the oncogenic drivers LMO2 and LMO1, respectively.

Myeloid p53 regulates macrophage polarization and venous thrombus resolution by inflammatory vascular remodeling in mice
Mukhopadhyay and colleagues use a murine model of venous thrombosis to demonstrate that the tumor suppressor p53 plays an important role in thrombus resolution through modulation of polarization of infiltrating macrophages.

Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding
Belderbos and colleagues use cellular barcoding and serial xenotransplantation to trace the clonal selection of leukemia cells in primary samples from patients with B-cell precursor acute lymphoblastic leukemia.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
In June’s Continuing Medical Education article, Guglielmelli and colleagues analyze a large cohort of patients with primary myelofibrosis (PMF) in the context of the 2016 World Health Organization (WHO) criteria distinguishing prefibrotic and overt PMF, confirming the utility of the criteria to predict differences in gene mutation patterns, natural history, and prognosis.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.